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CIn the post-genomic era, drug development and
diagnostic imaging have become more closely
linked in the search for targets. Since the 1940s,
nuclear imaging has been based on physiological
targets, some more easily saturable than others.
Recently, the search for drug targets has been
increasingly based on genomics, primarily on
genome-wide association studies, an approach used
in genetics research to look for associations between
specific genetic variations (most commonly single-
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nucleotide polymorphisms) and particular diseases
(1). Genomic technology has led to very important
therapeutic innovations, including the use of ima-
tinib mesylate (Gleevec, Novartis Oncology, East
Hanover, New Jersey) in Bcr-Abl chronic myeloid
leukemia and trastuzumab (Herceptin, Genentech,
San Francisco California) in Her2-positive breast
cancer, but the approach has not been widely
successful to date (2). In complicated psychiatric
disorders such as schizophrenia and bipolar dis-
order, many loci have been identified that meet
genome-wide significance but have not led to
effective drug development (3). More complete
links of physiology and disease are being pursued
(4,5). This is not to say that targeted drugs and
imaging probes were not developed before the
sequencing of the human genome; for example, in
cardiology, alpha- and beta-adrenoreceptor and
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to disclose.ngiotensin-converting enzyme (ACE) inhibitors
nd matching imaging probes have been devel-
ped (6,7).
Given the time constraints on multiple imaging
tudies, choosing a single target given the genetic
omplexity of many diseases is a challenge that
hould be addressed in iJACC papers. Imaging
ingle targets would be better suited for Mendelian
ingle-gene disorders. Nevertheless, matching tar-
eted imaging probes with effective drugs targeted
o a single-protein expression product such as ima-
inib mesylate, trastuzumab, lisinopril (ACE inhib-
tor), and alprenolol (beta-adrenergic receptor) have
otential clinical applications. Although a broad
ationale for a particular probe is often given in the
aper’s introduction, identifying a unique clinical
pplication will accelerate the translation to the
linic. The competitive environment should also be
ecognized. For example, in the case of trastu-
umab, an in vitro kit was approved at the time the
rug was approved so imaging of the primary
isease may not be cost-effective. To monitor the
reatment of high blood pressure with beta-
drenergic receptors or ACE inhibitors, a sphyg-
omanometer was used, and an imaging application
ad to be chosen carefully. A unique application, such
s monitoring a large field of view for disease burden
nd changes in disease burden, is best suited for
iagnostic imaging.
Whether the signal is from a nuclear, magnetic
esonance, or fluorescence signaling probe or a
ultiplex probe (8), validation of the probe(s) is
rucial. The technical requirements for validation
ary widely among investigators as evidenced by the
iversity in information published by the National
ancer Institute-sponsored Molecular Imaging and
ontrast Agents Database group’s publications on
he topic (9,10).
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617For nuclear reporters radiolabeled with single-
photon emission computed tomography and posi-
tron emission tomography radionuclides, there is a
well-defined list of metrics; this list includes criteria
for radiochemical yield, chemical yield, radiochem-
ical and chemical purity, and specific activity that
should be applied to magnetic resonance imaging
and fluorescent probes as well. For example, specific
activity can be interpreted as probes per molecule
including antibodies and peptides or per nanopar-
ticle rather than the more traditional radioactivity
per mass (MBq/mol). If chiral centers are present,
he stereochemistry should be described. For hu-
an use, the absence of organic volatiles, pyrogens,
nd bacteria should be included as well.
More diversity in literature data is seen in the
ext step of validating the targeting of the desired
rotein both in vitro and in vivo. In vitro, Motulsky
11) has defined saturation and competitive binding
o measure saturable binding, but this approach
oes not address specificity unless a large number of
otential binding sites are also studied. Specificity
ecomes more critical when validating a probe for a
pecific receptor subtype, and in this case knock-out
ice have been used effectively. In addition, satu-
ability and specificity in vitro do not directly
ddress the relationship between binding constants
nd target protein density in terms of external
maging potential. There are best-case rules of
humb such as Bmax/Ki (12) and more complicated
odels of in vivo data by Mintun et al. (13) and
ther groups (14).
Blocking studies, a term loosely used to define
ncreasing amounts of competing ligand injected
ither before, with, or after the signal-containing
robe, are used most often to demonstrate satu-
able binding. It is important that this is a
ingle-variable experiment in that the added mass
oes not alter confounding factors such as blood
ow, transport, metabolism, or multidrug resis-
ance pumps. These studies are conclusive if only
he target organ concentration of the signal-
ontaining probe decreases with increasing block-
ng mass. Agonists especially can cause pharma-
ological effects in higher mass amounts that can
hange the blood flow, permeability, and metab-
lism. Another approach that avoids some of the
hallenges is the use of animal models in which
he target protein, including specific subtypes,
as been knocked out.
Other investigators use probes (nuclear, magnetic
esonance imaging, or fluorescent) that have very
ow affinities for the target protein as a control, andthers use a target to normal tissue ratio or a tumor
ontaining the target compared with a tumor with-
ut the target. Others use active and inactive
tereoisomers for small molecules. All methods
ave challenges because the control probe must
ave the same pharmacokinetics as the targeted
robe, and the control tissue or tumor must have
he same blood flow and permeability. A pharma-
okinetic analysis of the probe and the control
ould be the best assurance of this.
This issue of iJACC contains an example of this
approach. Hara et al. (15) have presented their
evidence for molecular imaging of fibrin deposition
in deep vein thrombosis using a new fibrin-targeted
near-infrared fluorescence (NIRF) imaging strat-
egy. They presented a strong rationale for influenc-
ing patient care; namely, the development of a
thrombosis-specific molecular imaging agent to de-
tect and monitor thrombogenesis and fibrinolysis in
vivo could improve the diagnosis, risk stratification,
and treatment of thrombosis syndromes. They val-
idated the saturable and specific binding to thrombi
by blocking studies using a 100-fold excess of
unlabeled competitor peptide. In the previous issue
of iJACC, Dilsizian et al. (16) presented an equally
focused clinical goal of assessing myocardial ACE-1
up-regulation to monitor ACE as a function of
progressive heart failure using external imaging.
Because left ventricular ACE expression has been
found to be significantly enhanced in the failing
human myocardium in proportion to increasing
disease severity, monitoring ACE by noninvasive
imaging as a function of treatment should have
clinical impact. Dilsizian et al. (16) used another
approach to demonstrate specific and saturable
binding. ACE-1–overexpressing transgenic rats
were compared with wild-type Sprague-Dawley rats.
There was a significant increase in the uptake of the
radiolabeled lisinopril analogue in the heart of the
transgenic rats.
These validation steps are necessary but not
sufficient to produce a useful diagnostic probe if the
goal is to follow changes in the target protein as a
function of disease or treatment. The pharmacoki-
netic distribution must be relatively free from
changes in blood flow or permeability as a function
of disease or treatment to measure changes in the
target protein. If cell counting and the ability to
detect small volumes of target tissue is the goal,
then the highest affinity possible is ideal, but this is
the definition of a flow agent and therefore that
confounders must be evaluated in parallel.
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618Validation on all levels is not a straight-forward
study, and thus a wide diversity in the published
studies on new probes is inevitable. A recently
published text (17) contains the approaches taken
by several investigators following the Bench to
Bedside paradigm. But the goal is clear even if
the path is not. First, choose a disease in whichWichter T, Schober O. Radioligands
for imaging myocardial alpha- and
1
1
1
CRC Press, Taylor
2012:201–15.target most sensitive to disease progression, and
finally validate a targeted molecular imaging
probe that delivers unique clinical information by
external imaging.
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